Table 1.
Baseline Characteristics of Participants Who Completed the Study
| Characteristic | Mean (SD)
|
|||
|---|---|---|---|---|
| Participants Who Received GHRH (n = 67)
|
Participants Who Received Placebo (n = 70)
|
|||
| Normal Controls (n = 36) | Adults With MCI (n = 31) | Normal Controls (n = 40) | Adults With MCI (n = 30) | |
| Sex, No. | ||||
| Female | 20 | 19 | 21 | 18 |
| Male | 16 | 12 | 19 | 12 |
| Age,a y | 67.2 (7.9) | 70.2 (8.3) | 65.9 (6.9) | 69.2 (8.2) |
| Education, y | 16.1 (2.1) | 16.5 (2.6) | 16.4 (2.6) | 16.6 (2.3) |
| MMSE scorea | 28.9 (1.3) | 28.2 (1.9) | 29.1 (1.0) | 28.6 (1.2) |
| Story Recall scorea,b | 55.6 (12.2) | 42.8 (15.7) | 52.7 (14.2) | 44.1 (16.4) |
| Body fat,c % | 35.1 (10.1) | 38.2 (8.6) | 34.3 (9.7) | 34.3 (9.3) |
| Lean muscle,d kg | 47.9 (11.2) | 43.5 (10.0) | 48.1 (10.3) | 46.3 (12.4) |
| Fasting serum IGF-1 level, ng/mL | 153 (71) | 164 (89) | 178 (80) | 164 (77) |
| Fasting plasma insulin level, μIU/mL | 7.0 (4.2) | 6.7 (4.1) | 6.6 (5.6) | 8.0 (8.1) |
| Fasting plasma glucose level, mg/dL | 102 (9.1) | 102 (11.4) | 100 (10.3) | 99 (10.0) |
Abbreviations: GHRH, growth hormone–releasing hormone; IGF-1, insulinlike growth factor 1; MCI, mild cognitive impairment; MMSE, Mini-Mental Status Examination (maximum score, 30).
SI conversion factors: To convert IGF-1 to nanomoles per liter, multiply by 0.131; to convert insulin to picomoles per liter, multiply by 6.945; and to convert glucose to millimoles per liter, multiply by 0.0555.
P < .05 (baseline difference by diagnosis).
Immediate + delayed memory score on Story Recall, a test of verbal memory for thematic information (maximum score, 80).
Dual-energy x-ray absorptiometry measurement of total body fat, expressed as percentage of total body mass.
Dual-energy x-ray absorptiometry measurement of lean muscle mass.